

2. Larson HJ. A call to arms: Helping family, friends and communities navigate the COVID-19 infodemic. *Nat Rev Immunol* 2020;20:449–450.
3. Islam MS, Sarkar T, Khan SH, et al. COVID-19-related infodemic and its impact on public health: A global social media analysis [published online ahead of print, 2020 Aug 10]. *Am J Trop Med Hyg* 2020;103:1621–1629.
4. Peeples L. Face masks: What the data say. Available at: <https://www.nature.com/articles/d41586-020-02801-8>. Accessed November 16, 2020.
5. Centers for Disease Control and Prevention. Scientific brief: Community use of cloth masks to control the spread of SARS-CoV-2. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov-2.html>. Accessed November 17, 2020.
6. Eysenbach G. How to fight an infodemic: The four pillars of infodemic management. *J Med Internet Res* 2020;22:e21820.
7. Chu DK, Akl EA, Duda S, et al. COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* 2020;395:1973–1987.
8. Puri N, Coomes EA, Haghbayan H, et al. Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases. *Hum Vaccin Immunother* 2020;16:2586–2593.
9. Donovan J. Social-media companies must flatten the curve of misinformation. *Nature* 2020 Apr 14 [Epub ahead of print].
10. AMDA. Questions and answers about the COVID-19 vaccine for PALTC staff, patients, residents, and family members. Available at: [http://paltc.org/sites/default/files/QA%20about%20the%20COVID-19%20Vaccine%20for%20PALTC%20Patients%20Family%20Member%20and%20Staff%20\\_%202012\\_1\\_20%20FINAL.pdf](http://paltc.org/sites/default/files/QA%20about%20the%20COVID-19%20Vaccine%20for%20PALTC%20Patients%20Family%20Member%20and%20Staff%20_%202012_1_20%20FINAL.pdf). Accessed December 2, 2020.

Larry Lawhorne, MD, Steven Swedlund, MD  
 Department of Geriatrics, Wright State University Boonshoft School of  
 Medicine, Dayton, OH, USA

<https://doi.org/10.1016/j.jamda.2020.12.044>

## COVID-19 Pandemic and Management of Chronic Pain in Nursing Homes



### To the Editor:

The coronavirus disease (COVID-19) pandemic has disproportionately affected frail, older adults residing in nursing homes (NHs). The pandemic triggered many negative consequences beyond physical health, including social isolation, loneliness, and depression.<sup>1</sup> In the NH setting, many residents suffered physical, emotional, and psychological trauma due to active COVID-19 infection, repeated testing for the virus, and/or lack of visitation by family members and loved ones. This has further complicated chronic pain management in the NH setting.

As chronic pain is influenced by psychological, biological, and social elements,<sup>2</sup> NH residents can experience exacerbation of chronic pain during the COVID-19 pandemic requiring more pain medications, including opioids. Furthermore, residents with COVID-19 may need additional attention to pain management because of physical pain from infection<sup>3</sup> (eg, headaches and myalgias), limited mobility outside of the room because of infection control practices, psychosocial stress,<sup>4</sup> depression, or anxiety. Neurologic complications associated with COVID-19 infection, including peripheral neuralgia or post-stroke pain syndrome, can further exacerbate pain.<sup>3</sup> Javed et al<sup>4</sup> reported a higher number of narcotic prescriptions during the COVID-19 pandemic from March to April 2020 in part because of changes in public policy (eg, temporary waiver in Texas permitting telephone refills).

Management of chronic pain in the NH requires an interdisciplinary approach<sup>5</sup>, which has been particularly important during the pandemic. For instance, nursing staff can assist the medical team with the assessment and monitoring of exacerbation of chronic pain and other somatic symptoms associated with COVID-19 including but not limited to myalgias, arthralgias, referred pain, depression, and insomnia. Additional members of the Interdisciplinary Team have their unique contributions: pharmacists can assist with pharmacologic approaches, the physical therapists can use heat/cold therapy and therapeutic exercises, and psychologists can use cognitive behavioral therapy and psychological counseling.<sup>5</sup>

Nonpharmacologic interventions can alleviate mild pain; pharmacologic agents can be added to nonpharmacologic interventions to control moderate to severe pain. Opioids should be reserved for severe pain. Some opioids can affect the immune response and should be carefully considered as a treatment option for exacerbation of chronic pain during COVID-19 infection.<sup>6,7</sup> Opioids can also suppress cough associated with COVID-19 infection.<sup>8</sup> Risks vs benefits of each treatment option should be evaluated by the medical team and discussed with the resident and caregivers prior to its initiation.

During the COVID-19 pandemic, all medications should be assessed for their necessity,<sup>9</sup> including the need for continuation of opioids and other pharmacologic agents for chronic pain. Reducing the number of medications can decrease pill burden among the residents.<sup>10</sup> A decreased number of medication passes also reduces workload burden during staffing shortages arising from the pandemic.<sup>11,12</sup> It also helps decrease (1) the number of interactions with COVID-19–positive residents, (2) costs associated with personal protective equipment, and (3) potential exposure to the nursing staff.

Clinicians should be aware that several factors can hinder successful tapering of opioids during the pandemic, including but not limited to.

1. scarce availability of rehabilitation team for various non-pharmacologic approaches,
2. lack of support from family and loved ones owing to limited visitation policies, and
3. the requirement to limit out-of-the facility appointments (eg, pain specialists).

In summary, management of chronic pain should not be delayed in times of COVID-19, but the way we approach treatment has become increasingly complicated and requires an integrated multidisciplinary approach. Although undertreated chronic pain can lead to immune suppression, which can further complicate COVID-19 infection, opiate therapy can also lead to a blunted immune response and decreased cough reflex.<sup>5</sup> Chronic pain medications should not be stopped abruptly, as it can lead to exacerbation of pain and withdrawal symptoms. Person-centered pain management during the pandemic has been particularly challenging; however, it is critical to improving quality of life and function for older adults in nursing homes.

### References

1. Smith BJ, Lim MH. How the COVID-19 pandemic is focusing attention on loneliness and social isolation. *Public Health Res Pract* 2020;30:e3022008.
2. Clauw DJ, Häuser W, Cohen SP, Fitzcharles MA. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. *Pain* 2020;161:1694–1697.
3. Puntillo F, Giglio M, Brienza N, et al. Impact of COVID-19 pandemic on chronic pain management: Looking for the best way to deliver care. *Best Pract Res Clin Anaesthesiol* 2020;34:529–537.
4. Javed S, Hung J, Huh BK. Impact of COVID-19 on chronic pain patients: A pain physician's perspective. *Pain Manag* 2020;10:275–277.

5. Sheikh F, Brandt N, Vinh D, Elon RD. Management of Chronic Pain in Nursing Homes: Navigating Challenges to Improve Person-Centered Care. *J Am Med Dir Assoc* 2021 Jan 6 [Epub ahead of print].
6. Plein LM, Rittner HL. Opioids and the immune system—friend or foe. *Br J Pharmacol* 2018;175:2717–2725.
7. Chan DX, Lin XF, George JM, et al. Clinical challenges and considerations in management of chronic pain patients during a COVID-19 pandemic. *Ann Acad Med Singap* 2020;49:669–673.
8. El-Tallawy SN, Nalamasu R, Pergolizzi JV, et al. Pain management during the COVID-19 pandemic. *Pain Ther* 2020;9:453–466.
9. Brandt N, Steinman MA. Optimizing medication management during the COVID-19 pandemic: An implementation guide for post-acute and long-term care. *J Am Geriatr Soc* 2010;68:1362–1365.
10. Kua CH, Yeo CY, Tan PC, et al. Association of deprescribing with reduction in mortality and hospitalization: A pragmatic stepped-wedge cluster-randomized controlled trial. *J Am Med Dir Assoc* 2021;22:82–89.
11. Thomson MS, Gruneir A, Lee M, et al. Nursing time devoted to medication administration in long-term care: Clinical, safety, and resource implications. *J Am Geriatr Soc* 2009;57:266–272.
12. Bergman-Evans B. A nurse practitioner led protocol to address polypharmacy in long-term care. *Geriatr Nurs* 2020;41:956–961.

Fatima Sheikh, MD, MPH, CMD, Rebecca D. Elon, MD, MPH, CMD,  
Morgan J. Katz, MD, MHS  
*Department of Medicine, Johns Hopkins University School of  
Medicine, Baltimore, MD, USA*

Nicole Brandt, PharmD, MBA, BCGP, BCPP, FASCP  
*University of Maryland School of Pharmacy, Peter Lamy Center on  
Drug Therapy and Aging, Baltimore, MD, USA*

*Center for Successful Aging at MedStar Good Samaritan Hospital,  
Baltimore, MD, USA*

<https://doi.org/10.1016/j.jamda.2021.01.072>